Dehydroepiandrosterone supplementation in primary ovarian insufficiency (POI) patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-13003725

Enrollment

Unknown

Registered

2013-09-22

Start date

2010-03-04

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary ovarian insufficiency

Interventions

DHEA supplementation:DHEA

Eligibility

Sex/Gender

Female

Age

18 Years to 39 Years

Inclusion criteria

Inclusion criteria: China Han women with POF exclude of autoimmune diseases and chromosome abnormalities, who wanted to become pregnant, were enrolled.

Exclusion criteria

Exclusion criteria: Patients with chromosome abnormalities; Patients with severe endometriosis; Patients with thyroid dysfunction; Patients with hormone replacement therapy contraindications; Past history of ovarian tumors or after radiotherapy; Can not take the follow-up, or want to take other treatment during the follow-up period; Patients with immune system diseases.

Design outcomes

Primary

Measure	Time frame
Serum levels of FSH, LH and E 2;Ovarian ultrasound evaluation ;	—

Countries

China

Contacts

Public ContactYali Hu

Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School

yali_hu@hotmail.com+86 13951846008

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026